PharmaTher Holdings Ltd.

PHRM

CA71716H1082

Pharmaceuticals

Delayed Canadian Securities Exchange Other stock markets 01:15:48 06/06/2024 am IST			5-day change	1st Jan Change
0.22 ^CAD	0.00%		+7.32%	-30.16%

15/05	PharmaTher's Sairiyo Submits Clinical Trial Application in Australia For Phase 1 Study of Reformulated Cepharanthine	MT
10/05	PharmaTher Assigned FDA Approval Goal Date for its New Drug Application for Ketamine	MT

Newscope Capital Corporation has Changed its Name to PharmaTher Holdings Ltd

April 05, 2021 at 09:30 am IST

On April 05, 2021, Newscope Capital Corporation changed its name to PharmaTher Holdings Ltd.

Latest news about PharmaTher Holdings Ltd.

PharmaTher's Sairiyo Submits Clinical Trial Application in Australia For Phase 1 Study of Reformulated Cepharanthine	15/05	MT
PharmaTher Assigned FDA Approval Goal Date for its New Drug Application for Ketamine	10/05	MT
PharmaTher Brief: Announcing Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine	10/05	MT
PharmaTher Holdings Ltd. Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine	10/05	CI
PharmaTher's Sairiyo Therapeutics Completes Regulatory Package For Phase 1 Study of Reformulated Cepharanthine in Australia	01/05	MT
PharmaTher Holdings Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	23/04	CI
PharmaTher Updated on its Priority Original Abbreviated New Drug Application for Ketamine	16/04	MT
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine	16/04	CI
PharmaTher Provides Update For PD-001	21/02	MT
PharmaTher Provides Update on its Priority Original Abbreviated New Drug Application For Ketamine	12/02	MT
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine	12/02	CI
PharmaTher Holdings Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023	27/01	CI
PharmaTher Provided Update for Expected FDA Approval of Ketamine	10/01	MT
PharmaTher Holdings Ltd. Provides an Update for Its Lead Drug, Ketamine	10/01	CI
PharmaTher Holdings Ltd. Reports Earnings Results for the First Quarter Ended August 31, 2023	31/23/31	CI
PharmaTher Holdings Ltd. Reports Earnings Results for the Full Year Ended May 31, 2023	29/23/29	CI
PharmaTher Announced FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for Ketarx	27/23/27	MT
PharmaTher Brief: Notes FDA assigns GDUFA goal date of April 29, 2024	27/23/27	MT
PharmaTher Brief: Announcing FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX (Ketamine)	27/23/27	MT
PharmaTher Holdings Ltd. Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX(TM)	27/23/27	CI
PharmaTher Submits Priority Original Abbreviated New Drug Application for Ketarx (Ketamine) to FDA	06/23/06	MT
PharmaTher Brief: Submitting Priority Original Abbreviated New Drug Application for KETARX (Ketamine) to FDA	06/23/06	MT
PharmaTher Holdings Ltd. Submits Priority Original Abbreviated New Drug Application for KETARX? to the FDA	06/23/06	CI
PharmaTher Reports "Positive" Research Results for PharmaPatch with DMT and Strategic Investment into Sairiyo Therapeutics	18/23/18	MT
PharmaTher Brief: Announcing "Positive" Research Results for PharmaPatch with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics	18/23/18	MT

Chart PharmaTher Holdings Ltd.

Duration

Period

More charts

PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The Company is also commercializing PharmaPatch (microneedle patch) with its partners to deliver psychedelics and drugs to treat infectious diseases.

Sector

Pharmaceuticals

Calendar

26/09/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PHARMATHER HOLDINGS LTD.	-30.16%	1.42Cr
ELI LILLY AND COMPANY	+42.93%	75TCr
NOVO NORDISK A/S	+34.11%	61TCr
JOHNSON & JOHNSON	-6.85%	36TCr
MERCK & CO., INC.	+19.05%	33TCr
ABBVIE INC.	+6.63%	29TCr
ASTRAZENECA PLC	+18.08%	25TCr
ROCHE HOLDING AG	-3.44%	21TCr
NOVARTIS AG	+11.35%	21TCr
PFIZER, INC.	+2.52%	17TCr

Other Pharmaceuticals

PharmaTher Holdings Ltd.

Equities

PHRM

CA71716H1082

Pharmaceuticals

Newscope Capital Corporation has Changed its Name to PharmaTher Holdings Ltd

Latest news about PharmaTher Holdings Ltd.

Chart PharmaTher Holdings Ltd.

Company Profile

Income Statement Evolution

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals